A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity
Latest Information Update: 25 Mar 2026
At a glance
- Drugs CT-388 (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacokinetics
- Acronyms BP46585
- Sponsors Roche
Most Recent Events
- 25 Mar 2026 New trial record